CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas

BACKGROUND: CDK4/6 inhibitors (CDK4/6i) have been established as standard treatment against advanced Estrogen Receptor-positive breast cancers. These drugs are being tested against several cancers, including in combinations with other therapies. We identified the T172-phosphorylation of CDK4 as the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pita, Jaime M., Raspé, Eric, Coulonval, Katia, Decaussin-Petrucci, Myriam, Tarabichi, Maxime, Dom, Geneviève, Libert, Frederick, Craciun, Ligia, Andry, Guy, Wicquart, Laurence, Leteurtre, Emmanuelle, Trésallet, Christophe, Marlow, Laura A., Copland, John A., Durante, Cosimo, Maenhaut, Carine, Cavaco, Branca M., Dumont, Jacques E., Costante, Giuseppe, Roger, Pierre P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641312/
https://www.ncbi.nlm.nih.gov/pubmed/37964967
http://dx.doi.org/10.3389/fendo.2023.1247542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641312/
https://www.ncbi.nlm.nih.gov/pubmed/37964967
http://dx.doi.org/10.3389/fendo.2023.1247542

Ejemplares similares